This study was funded by The Interesting Patient Study (TIPS) and the Division of Physician Scientists (DPS) at Washington University School of Medicine. TIPS and DPS also provided mentorship support. The Genome Technology Access Center (GTAC) at the McDonnell Genome Institute at Washington University School of Medicine provided help with genomics services. GTAC is partially supported by NCI Cancer Center Support Grant #P30 CA91842 to the Siteman Cancer Center and by ICTS/CTSA Grant# UL1TR002345 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. This publication is solely the responsibility of the authors and does not necessarily represent the official view of NCRR or NIH. Dr Stitziel has received investigator-initiated research funding from Regeneron Pharmaceuticals unrelated to the content of this study. Dr Javaheri serves on the scientific advisory board for Mobius Scientific, has received research funding from AstraZeneca, Bitterroot, Inc., and has patents related to the use of apolipoprotein for the treatment of heart failure and eye diseases. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.